Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cartistem with Microfracture for Osteochondral Lesion of Talus
NCT02338375Phase 1Unknown
- Sponsor
- Samsung Medical Center
- Start
- Dec 2012
- Primary completion
- Aug 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Cartistem in osteochondral lesion of the talus (OLT) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: American Orthopaedic Foot and Ankle Society HINDFOOT/ANKLE SCALE at Week 48. Status: unknown.
02
Drugs
Cartistem
03
Conditions
osteochondral lesion of the talus (OLT)
Beyond the preview
Go deeper on NCT02338375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338375.